Ignite Creation Date:
2024-05-06 @ 10:27 AM
Last Modification Date:
2024-10-26 @ 12:30 PM
Study NCT ID:
NCT03268954
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-30
First Post:
2017-08-30
Brief Title:
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes HR MDS Chronic Myelomonocytic Leukemia CMML or Low-Blast Acute Myelogenous Leukemia AML
Sponsor:
Takeda
Organization:
Takeda
Organization Data
Organization:
Takeda
Class:
INDUSTRY
Study ID:
Pevonedistat-3001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Takeda
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Takeda Development Center Americas Inc | INDUSTRY |